UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR ATTORNEY DOCKET		CONFIRMATION NO.
10/022,481	12/18/2001	Miquel Sales Amill	INL-048	3281
22832 7590 07/09/2008 Kirkpatrick & Lockhart Preston Gates Ellis LLP (FORMERLY KIRKPATRICK & LOCKHART NICHOLSON GRAHAM)			EXAMINER	
			FOSTER, CHRISTINE E	
STATE STREET FINANCIAL CENTER One Lincoln Street BOSTON, MA 02111-2950		ART UNIT	PAPER NUMBER	
		1641		
			NOTIFICATION DATE	DELIVERY MODE
			07/09/2008	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

## Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)	
	10/022,481	SALES AMILL ET AL.	
	Examiner	Art Unit	
	Christine Foster	1641	

		Chilotine 1 deter	1041
	The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence address
THE R	EPLY FILED <u>16 June 2008</u> FAILS TO PLACE THIS APF	PLICATION IN CONDITION FOR A	LLOWANCE.
a f	The reply was filed after a final rejection, but prior to or on pplication, applicant must timely file one of the following pplication in condition for allowance; (2) a Notice of Appetr Continued Examination (RCE) in compliance with 37 Ceriods:	replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	t, or other evidence, which places the with 37 CFR 41.31; or (3) a Request
a) 🛚	The period for reply expiresmonths from the mailing	date of the final rejection.	
b) 🛭	no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or (	ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection.
have be under 3 set forth may red	MONTHS OF THE FINAL REJECTION. See MPEP 706.07(cons of time may be obtained under 37 CFR 1.136(a). The date ten filed is the date for purposes of determining the period of extra 7 CFR 1.17(a) is calculated from: (1) the expiration date of the solin (b) above, if checked. Any reply received by the Office later duce any earned patent term adjustment. See 37 CFR 1.704(b). E OF APPEAL	on which the petition under 37 CFR 1.1 tension and the corresponding amount of shortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropriate extension fee nally set in the final Office action; or (2) as
	he Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be	filed within two months of the date of
fi N	ling the Notice of Appeal (37 CFR 41.37(a)), or any exter lotice of Appeal has been filed, any reply must be filed w DMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since a
(	The proposed amendment(s) filed after a final rejection, by They raise new issues that would require further core they They raise the issue of new matter (see NOTE belo	nsideration and/or search (see NO	
(	c) They are not deemed to place the application in bet appeal; and/or d) They present additional claims without canceling a	ter form for appeal by materially red	
(	NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	scied dains.
4. 🔲	The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Co	mpliant Amendment (PTOL-324).
	Applicant's reply has overcome the following rejection(s):		,
r	Newly proposed or amended claim(s) would be all on-allowable claim(s).		
† T C C	For purposes of appeal, the proposed amendment(s): a) ow the new or amended claims would be rejected is provide status of the claim(s) is (or will be) as follows:  Claim(s) allowed:  Claim(s) objected to:  Claim(s) rejected: 1.3,5-8,10-18,22,32,34 and 35.  Claim(s) withdrawn from consideration:		I be entered and an explanation of
	AVIT OR OTHER EVIDENCE		
b	he affidavit or other evidence filed after a final action, bu ecause applicant failed to provide a showing of good and as not earlier presented. See 37 CFR 1.116(e).		
€	he affidavit or other evidence filed after the date of filing ntered because the affidavit or other evidence failed to o howing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails to provide a
	The affidavit or other evidence is entered. An explanation EST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attached.
	The request for reconsideration has been considered buse Continuation Sheet.	t does NOT place the application in	condition for allowance because:
	Note the attached Information <i>Disclosure Statement</i> (s). (Other:	(PTO/SB/08) Paper No(s)	
	g V Le/ rvisory Patent Examiner, Art Unit 1641		

Continuation of 5. Applicant's reply has overcome the following rejection(s): (1) the rejection of claim 17 under 112, 1st paragraph; (2) the rejections of claims 1 and 22 under 112, 2nd paragraph; and (3) the objections to claims 14-15 and 17.

Continuation of 11. does NOT place the application in condition for allowance because:

With respect to the rejections under 35 USC 112, 1<sup>st</sup> paragraph, Applicant's arguments have been fully considered but are not persuasive for reasons of record. Applicant points to Example 4 of the Written Description Training Materials and argues that the disclosure of a single nucleic acid sequence sufficiently describes a claimed invention comprising that nucleic acid sequence (Reply, pages 6-7). However, the facts of the instant case differ from those in Example 4 because here, the specification and claims as originally filed disclose only a species and do not even suggest or introduce the concept of the genus that is presented in the amended claims. In particular, although the specification discloses a first member that "is" protein S, there is no suggestion or direction to the genus of first members that "comprise" protein S in addition to other amino acids or elements, as now claimed in the amended claims. Similarly, while C4BP per se is disclosed in the specification, the concept of the genus of members that "comprise" C4BP is not introduced. Moreover, in regards to the instant method claims, there is no suggestion in the specification to use a second member that "comprises" C4BP in a method to detect an unbound form of a first member that "comprises" protein S. Although first and second members are discussed generally, and exemplified as being protein S and C4BP, respectively, there is no introduction of the genus first and second members that "comprise" each of these species. The Examiner maintains that this use of open transitional language in the amended claims, which was not present in the specification as originally filed, represents new matter.

Applicant further argues that the specification teaches methods that include proteins, namely C4BP and Protein S, and that a person of ordinary skill in the art would be able to readily predict and visualize other proteins that read on the claimed invention. This is not found persuasive because as discussed above, there is no disclosure in the specification of members that "comprise" protein S or C4BP in addition to other amino acids or elements and thus no introduction of the genera now claimed.

Applicant further argues that support for particles comprising at least latex can be found in the specification as originally filed; however, the Examiner was unable to find support where indicated since the specification does not employ open transitional language in referring to latex particles but only discusses particles made of latex per se. Although the use of conjugates and/or derivatives of proteins is discussed at [0063] as noted by Applicant, the instant claims are not limited to conjugates or derivatives. Furthermore, conjugates or derivatives of binding members are discussed for use as reagents used to detect the analyte, but there is no direction to detect conjugates or derivates as analytes. In particular, the indicated passages do not disclose the concept of detecting analytes that "comprise" unbound protein S.

With respect to the rejections under 35 USC 103 as being unpatentable over David et al. in view of Giri et al., Applicant's arguments (Reply, pages 10-11) were previously advanced in the Reply of 1/24/08 and are not persuasive for reasons of record (see the previous Office action at pages 21-24).

With respect to the rejections of claims 14-17 under 35 USC 103 as being unpatentable over David et al. in view of Giri et al. and Mischak et al., Applicant's arguments (Reply, page 12) were previously advanced in the Reply of 1/24/08 and are not persuasive for reasons of record (see the previous Office action at page 24).

With respect to the rejections of claim 35 under 35 USC 103 as being unpatentable over David et al. in view of Giri et al. and Cambiaso et al., Applicant's arguments (Reply, pages 12-13) were previously advanced in the Reply of 1/24/08 and are not persuasive for reasons of record (see the previous Office action at pages 24-25).

Applicant does not separately argue the limitations of dependent claim 13.

With respect to the non-statutory obviousness-type double patenting rejections, Applicant correctly notes that a double patenting rejection can be overcome by filing a terminal disclaimer (Reply, pages 8-9). However, the rejections are maintained for reasons of record because no terminal disclaimer has yet been made of record.